Open
Do investigational compounds cause more adverse events & safety than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 2
- Inconclusive
- 2
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 150
- With posted results
- 41
- Published papers
- 1
Of 58 decided analyses: 9 favor investigational compounds, 47 find no difference, 2 favor the comparator.
Papers
- Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations.Observational study · 2025
Trials
- A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes MellitusNCT01982630 · 61 posted results
- A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes MellitusNCT03235050 · 16 posted results
- A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes MellitusNCT02492763 · 10 posted results
- A Multicenter, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed DyslipidemiaNCT00479882 · 12 posted results
- A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed HyperlipidemiaNCT00289900 · 5 posted results
- A Phase 2 Dose Response Study of LY2484595 in Japanese SubjectsNCT01375075 · 4 posted results
- A Randomised Double-blind Placebo Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (RECAM)NCT04807348
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With MetforminNCT02205528